17th Sep 2018 11:50
LONDON (Alliance News) - AstraZeneca PLC said Sunday its trial of PT010 triple combination therapy in chronic obstructive pulmonary disease met eight of the nine primary lung function endpoints.
The KRONOS Phase III trial evaluated the efficacy and safety of triple combination therapy PT010 versus dual combination therapies in moderate to very severe chronic obstructive pulmonary disease, a progressive illness which can cause obstruction of airflow in the lungs resulting in debilitating breathlessness.
The pharmaceutical firm said that in a "key secondary endpoint", PT010 showed a 52% reduction in the rate of chronic obstructive pulmonary disease exacerbations compared to the dual therapy.
Colin Reisner, head of Respiratory Global Medicines, said: "We are encouraged by the results of the KRONOS trial which demonstrate PT010's efficacy in improving lung function and its potential value as a triple combination therapy for patients with COPD."
AstraZeneca anticipates making the first regulatory submissions for PT010 in the second half of 2018.
AstraZeneca shares were trading 0.9% lower at 5,596.00 pence each on Monday.
Related Shares:
Astrazeneca